金城医药：子公司金城金素收到注射用头孢呋辛钠药品补充申请批准通知书

Core Viewpoint - The company announced that its subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a supplemental application for injectable Cefuroxime Sodium, which is a proprietary drug of the company [1] Group 1 - The approved drug is indicated for infections caused by various bacteria and can be used for infection prevention in surgical procedures [1] - The revision of quality standards is expected to positively impact product quality [1] - Sales of the drug may be influenced by policy and market conditions, indicating potential risks for investors [1]